Protein findings could open door to new class of antibiotics

In the face of growing resistance of bacteria to certain antibiotics, researchers at Oregon State University have made a breakthrough while studying peroxiredoxin.

Using X-ray crystallography, a technique that shows structures down to their atoms, researchers were studying what role peroxiredoxin could play in developing stronger antibiotics. Peroxiredoxin, which helps destroy hydrogen peroxide in healthy cells, reacts differently when placed in bacteria. There, peroxiredoxin provides a defense from our immune cells and increases the risk of the bacteria causing infections.  

While observing peroxiredoxin, researchers noticed that when it stops moving, it loses all function and causes cell death. This stoppage in mobility within bacterial cells means the bacteria loses immunity and is destroyed by the peroxiredoxin. Researchers were also able to uncover a special region of the bacterial peroxiredoxins that can be targeted to destroy the cells.

Researchers focused on developing a method to target specific damaging cells while leaving healthy cells untouched, which could potentially lead to the development of new antibiotics.

"There's a lot of potential for this to be foundational work, something we can build on to create a new class of antibiotics," said Arden Perkins, lead author, in collaboration with Andrew Karplus, a distinguished professor of biochemistry in the OSU College of Science. "The key concept is selectively restraining the motions of peroxiredoxins in some cells, inactivating its function and leading to the death of the cells you want to kill."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Trimed Popup
Trimed Popup